Regarding the questions about why early detection is important,...

Regarding the questions about why early detection is important, I was doing some digging into Cognoa’s product and their 2021 FDA approval, and found this PR NewsWire story which gives some good detail about why early diagnosis & intervention is important, and how automated tools can allow earlier intervention, as well as boosting the reliability of diagnosis. Another important angle of the technological approach to diagnosis (apps etc) is that it can even the playing field for underrepresented demographics (namely females and non-whites) as well as deprived folks who get diagnosed much later (if ever).

Anyway I thought I’d share the link here, as it helps add substance to the narrative - that is to say, to assess if BB1 has a compelling idea that the world needs & wants. Would be interesting to see how Cognoa’s (and any other competitors’) products are faring in the market, given that Cognoa got FDA approval nearly 3 years ago, and BB1 is still years away from achieving it.

https://www.prnewswire.com/news-releases/cognoa-receives-fda-marketing-authorization-for-first-of-its-kind-autism-diagnosis-aid-301304351.html

Also, a piece about EarliTech Diagnostics’s 2022 FDA approval, that goes into why early detection is a good thing: https://www.fiercebiotech.com/medtech/fda-clears-digital-tool-help-doctors-diagnose-autism-kids-young-16-months